Emergent BioSolutions (NYSE:EBS) Coverage Initiated by Analysts at HC Wainwright

Research analysts at HC Wainwright began coverage on shares of Emergent BioSolutions (NYSE:EBS) in a note issued to investors on Monday, Marketbeat reports. The firm set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 56.90% from the stock’s previous close.

Several other research analysts have also weighed in on EBS. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday.

Emergent BioSolutions Trading Up 3.4 %

EBS opened at $9.56 on Monday. The firm’s fifty day moving average is $9.20 and its two-hundred day moving average is $8.93. The firm has a market cap of $518.00 million, a PE ratio of -2.33 and a beta of 1.59. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. bought a new position in shares of Emergent BioSolutions in the 2nd quarter valued at about $41,000. Verus Capital Partners LLC bought a new position in Emergent BioSolutions in the second quarter valued at approximately $68,000. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth approximately $96,000. FORA Capital LLC bought a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $103,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Emergent BioSolutions in the second quarter valued at $93,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.